Special Issue "New Trends in Production and Applications of Metal Radionuclides for Nuclear Medicine"
Deadline for manuscript submissions: 30 November 2018
Dr. Licia Uccelli
Dr. Petra Martini
Legnaro National Laboratories of the National Institute of Nuclear Physics (INFN-LNL), Viale dell'Università, 2, 35020 Legnaro (PD) ITALY and University of Ferrara, Dpt. of Morphology, Surgical and Experimental Medicine, Via L. Borsari, 46, 44121, Ferrara, Italy
Interests: radioisotopes cyclotron-production; nuclear medicine; radiometals separation; synthesis module automation; radiopharmaceuticals
Nuclear Medicine is one of the most important imaging modalities and therapeutic approaches for the treatment of many critical diseases. The success of nuclear medicine in clinics has been intimately linked to the availability of new radionuclides and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals is constantly evolving thanks to the great contribution of specialists coming from different disciplines, such as radiochemistry, inorganic and organic chemistry, biochemistry, pharmacology, nuclear medicine, physics, etc. In particular, the use of radiometals has experienced a great increase as a result of the development of radionuclides production technologies. Their employment in all Nuclear Medicine branch (SPECT/PET diagnostic, therapy and theranostics) is regulated by their physical characteristics, such as half-life, radiation emission energy and type (γ, β+, β-, auger, α), availability and chemical ability to coordinate with ligands.
The actual trend in the nuclear medicine research field is the use of radiometals for PET and SPECT, such as 68Ga, 64Cu, 89Zr, 44Sc, 86Y, 52Mn, 99mTc, etc., for therapy, such as 177Lu, 90Y ,89Sr, 223Ra, 225Ac, etc., and for theranostics, such as 67Cu, 47Sc, theranostics pairs, etc.
You are cordially invited to contribute to this Special Issue “New Trends in Production and Applications of Metal Radionuclides for Nuclear Medicine” with original articles, as well as reviews and short communications. Areas of interest include, but are not limited to:
- Radiometals production: methods and technology
- Radiometals separation: methods and technology
- Radiopharmaceuticals synthesis automation: methods and technology
- Theranostics radiopharmaceuticals
- Multimodality imaging radiopharmaceuticals
- Innovative radio-probes for nuclear imaging or therapy
- Individualized Dosimetry for Theranostics
For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on the website.
Dr. Licia Uccelli
Dr. Alessandra Boschi
Dr. Petra Martini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Nuclear Medicine
- PET and SPECT radiopharmaceuticals
- Theranostics tracers
- Radionuclides therapy
- Radionuclides imaging
- Multimodality approaches
- Personalized medicine
- Automation technology
- Production technology
- Separation technology
- Labelling techniques
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Affiliation: Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy
Affiliation: Bonn Medical School, Germany
Affiliation: Erasmus MC, Department of Nuclear Medicine, Netherlands